Nicardipine

Source: Wikipedia, the free encyclopedia.
Nicardipine
Clinical data
Trade namesCardene
AHFS/Drugs.comMonograph
MedlinePlusa695032
Routes of
administration		Oral, intravenous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding>95%
Elimination half-life8.6 hours
Identifiers
  • 2-[benzyl(methyl)amino]ethylmethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
JSmol)
Melting point136–138 °C (277–280 °F)
  • O=C(OCCN(Cc1ccccc1)C)\C2=C(\N/C(=C(/C(=O)OC)C2c3cccc([N+]([O-])=O)c3)C)C
  • InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3 checkY
  • Key:ZBBHBTPTTSWHBA-UHFFFAOYSA-N checkY
  (verify)

Nicardipine (Cardene) is a

Raynaud's phenomenon. It is available in by mouth and intravenous formulations. It has been used in percutaneous coronary intervention.[1]

Its mechanism of action and clinical effects closely resemble those of

beta-blocker.[3][2]

It was patented in 1973 and approved for medical use in 1981.[4]

Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.[5]

See also

References

  1. S2CID 37071966
    .
  2. ^
    ISBN 978-0-07-182137-7
    .
  3. ^
    ISBN 978-1-2642-6938-9
    .
  4. ISBN 978-3-527-60749-5
    .
  5. ^ "Nicardipine". Medline Plus. U.S. National Library of Medicine.